FDA Staff Backs Broader Use Of Roche Eye Drug

Law360, New York (July 24, 2012, 5:24 PM EDT) -- Swiss pharmaceutical giant Roche Holding AG’s blockbuster eye drug Lucentis may become the first approved to treat a diabetes-related vision loss condition, after a U.S. Food and Drug Administration brief released Tuesday ahead of an FDA committee meeting showed positive trial results.

Lucentis improved vision in some test subjects with diabetic macular edema, a condition in which swelling in the center of the retina, the macula, causes progressively worse blurred vision, the FDA said. While laser treatment is already available to slow or stop the condition,...
To view the full article, register now.